<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030862</url>
  </required_header>
  <id_info>
    <org_study_id>01-123</org_study_id>
    <secondary_id>CDR0000069204</secondary_id>
    <secondary_id>PHARMACIA-440E-ONC-0020-319</secondary_id>
    <secondary_id>NCI-G01-2050</secondary_id>
    <nct_id>NCT00030862</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus</brief_title>
  <official_title>Phase II Single-Arm Trial Of CPT-11 (Irinotecan HC1; Camptosar Injection)/Cisplatin In Patients With Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and cisplatin in&#xD;
      treating patients who have locally advanced unresectable or metastatic cancer of the&#xD;
      esophagus that has not been previously treated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective tumor response rate in patients with previously untreated&#xD;
           locally advanced unresectable or metastatic esophageal cancer treated with irinotecan&#xD;
           and cisplatin.&#xD;
&#xD;
        -  Determine the dysphagia relief in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to progression and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cisplatin IV over 1-2 hours and irinotecan IV over 30 minutes on days 1 and&#xD;
      8. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus&#xD;
&#xD;
               -  Previously untreated&#xD;
&#xD;
               -  Locally advanced unresectable or metastatic disease&#xD;
&#xD;
               -  More than 50% of tumor must involve esophagus or gastroesophageal (GE) junction&#xD;
                  if tumor extends below the GE junction into the proximal stomach&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are not considered measurable disease:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusions&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
                    -  Tumor lesions in previously irradiated areas&#xD;
&#xD;
          -  No carcinomatous meningitis or untreated brain metastases&#xD;
&#xD;
               -  Brain metastases allowed if asymptomatic and patient is on stable or tapering&#xD;
                  dose of steroids&#xD;
&#xD;
          -  Large pleural effusions must have been previously drained and sclerosed or otherwise&#xD;
             controlled&#xD;
&#xD;
               -  Small, stable, asymptomatic pleural effusions allowed&#xD;
&#xD;
          -  Dysphagia allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  No known Gilbert's disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Calcium less than 12.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of significant cardiovascular disease&#xD;
&#xD;
          -  No inadequately controlled hypertension&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No ventricular cardiac arrhythmias requiring medication&#xD;
&#xD;
          -  No history or treatment for congestive heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No interstitial pneumonia&#xD;
&#xD;
          -  No fibroid lung&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No serious active infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (random blood sugar at least 300 mg)&#xD;
&#xD;
          -  No peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  No other malignancy within the past 3 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or any other malignancy&#xD;
             that does not carry a worse prognosis than advanced esophageal cancer&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study&#xD;
&#xD;
          -  No other concurrent disease that would preclude study&#xD;
&#xD;
          -  No psychiatric illness or other significant mental impairment that would preclude&#xD;
             study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent phenytoin or phenobarbital&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Ilson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

